3,564 Shares in Revvity, Inc. (NYSE:RVTY) Bought by Pullen Investment Management LLC

Pullen Investment Management LLC bought a new stake in Revvity, Inc. (NYSE:RVTY - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm bought 3,564 shares of the company's stock, valued at approximately $377,000.

Other large investors also recently modified their holdings of the company. T. Rowe Price Investment Management Inc. grew its stake in Revvity by 16.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 20,761,308 shares of the company's stock worth $2,317,170,000 after purchasing an additional 2,969,326 shares during the period. Vanguard Group Inc. raised its holdings in Revvity by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 14,290,211 shares of the company's stock valued at $1,594,930,000 after acquiring an additional 156,679 shares during the period. Price T Rowe Associates Inc. MD grew its position in Revvity by 17.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,631,597 shares of the company's stock worth $851,764,000 after acquiring an additional 1,151,821 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of Revvity by 0.4% in the fourth quarter. Janus Henderson Group PLC now owns 6,358,952 shares of the company's stock worth $709,725,000 after buying an additional 23,650 shares during the period. Finally, EdgePoint Investment Group Inc. lifted its position in shares of Revvity by 51.1% in the 4th quarter. EdgePoint Investment Group Inc. now owns 4,058,231 shares of the company's stock worth $452,939,000 after purchasing an additional 1,372,456 shares during the period. 86.65% of the stock is currently owned by institutional investors.

Revvity Trading Up 2.8%

Shares of Revvity stock traded up $2.62 on Monday, hitting $96.15. The stock had a trading volume of 538,301 shares, compared to its average volume of 953,770. The stock has a 50 day moving average of $93.20 and a 200 day moving average of $106.73. The firm has a market capitalization of $11.33 billion, a P/E ratio of 43.48, a PEG ratio of 3.82 and a beta of 0.97. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60. Revvity, Inc. has a twelve month low of $87.70 and a twelve month high of $129.50.

Revvity (NYSE:RVTY - Get Free Report) last announced its earnings results on Monday, April 28th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.05. The firm had revenue of $664.76 million during the quarter, compared to analyst estimates of $662.30 million. Revvity had a return on equity of 7.68% and a net margin of 9.81%. The business's revenue was up 2.3% compared to the same quarter last year. During the same period last year, the firm posted $0.98 EPS. Sell-side analysts expect that Revvity, Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 8th. Shareholders of record on Friday, July 18th will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.29%. The ex-dividend date of this dividend is Friday, July 18th. Revvity's dividend payout ratio (DPR) is 11.91%.

Analyst Upgrades and Downgrades

RVTY has been the topic of several research reports. The Goldman Sachs Group dropped their target price on shares of Revvity from $140.00 to $125.00 and set a "buy" rating on the stock in a report on Tuesday, April 29th. Robert W. Baird lowered their price objective on shares of Revvity from $127.00 to $125.00 and set an "outperform" rating for the company in a research report on Tuesday, April 29th. Wells Fargo & Company decreased their target price on shares of Revvity from $130.00 to $102.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Wall Street Zen cut Revvity from a "buy" rating to a "hold" rating in a research report on Saturday, May 24th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Revvity from $120.00 to $100.00 and set a "neutral" rating for the company in a report on Tuesday, April 29th. Five analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Revvity currently has a consensus rating of "Moderate Buy" and an average target price of $125.64.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.